Terminal
Stocks
Spotlight
Research

Stocks
Healthcare
NASDAQ
URGN

Market Cap: $2.06B

UL

UroGen Pharma Ltd.

URGN

NASDAQUSD

Overview News Analyst Reports Financials Politician Trades Insider Trades Executive Patents Earnings Surprise

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

Stocks About Advertisers Brokers Contact

Legal

Terms of Service Privacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Financials

Profitability

Gross Profit Margin90.85%

EBITDA Margin-37.47%

EBIT Margin-38.55%

Pre-tax Margin-51.98%

Net Profit Margin-51.73%

Earnings Yield-4.58%

Valuation Multiples

Price / Book-16.10

Price / Sales10.92

Price / Earnings-21.37

PEG-0.42

Forward PEG0.02

EV / Sales11.54

EV / EBITDA-30.81

EV / Operating Cash Flow-13.71

EV / Free Cash Flow-13.69

Price / Free Cash Flow-12.95

Price / Operating Cash Flow-13.41

Cash Flow & Capital

Free Cash Flow / Share-$3.16

Operating Cash Flow / Share-$3.15

Free Cash Flow Yield-7.72%

Capex / Revenue0.12%

Capex / Operating Cash Flow-0.14%

Capex / Depreciation0.08

Stock Compensation / Revenue8.54%

Dividend Payout Ratio0.00%

Dividend Yield0.00%

Liquidity & Leverage

Current Ratio3.80

Quick Ratio3.41

Cash Ratio1.28

Debt / Assets0.78

Debt / Capital3.08

Debt / Equity-1.48

Long-Term Debt / Capital3.35

Debt / Market Cap9.16%

Net Debt / EBITDA-1.65

Solvency Ratio-0.25

Financial Leverage-1.91

Efficiency & Working Capital

Asset Turnover0.75

Fixed Asset Turnover22.95

Inventory Turnover0.70

Receivables Turnover2.13

Payables Turnover0.43

Days Sales Outstanding171.65

Days Inventory Outstanding519.45

Days Payables Outstanding843.84

Operating Cycle691.1

Cash Conversion Cycle-152.75

Working Capital Turnover1.05

Returns & Quality

Return on Equity81.78%

Return on Assets-38.65%

Return on Invested Capital-34.41%

ROCE-34.96%

Return on Tangible Assets-38.65%

Operating Return on Assets-26.33%

Income Quality1.63

Tax Burden1.00

Interest Burden1.35

Balance Sheet & Intrinsic Metrics

Enterprise Value$2.18B

Invested Capital$181.74M

Working Capital$173.51M

Tangible Asset Value$-132.4M

Net Current Asset Value$-149.56M

Graham Net-Net-$3.93

Book Value / Share-$2.63

Tangible Book Value / Share-$2.63

Cash / Share$2.14

Financial Health Scores

Piotroski Score2

Altman Z-Score-1.70

Revenue$188.73M

EBIT$-72.76M

Market Cap$2.06B

Working Capital$173.51M

Retained Earnings$-997.64M

Total Assets$252.59M

Total Liabilities$384.99M